HomeAI · summaries
Storia in 4 fonti
FDA clears PrecivityAD2, Alzheimer's disease blood test for as early as age 40 years
The FDA has cleared PrecivityAD2, a single blood test designed to help health care professionals rule in or rule out an Alzheimer’s disease diagnosis, according to a press release from the test’s developer, C2N. PrecivityAD2 is the first Alzheimer’s blood test to be cleared by the FDA for symptomatic adults aged 40 years and older, according to the press release.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
- ·
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early…
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
